Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69850 | 0.84 | — | — | |
| SCHEMBL8802637 | 0.81 | HTR2A (0.38) | — | |
| SCHEMBL28247874 | 0.78 | CACNA1H (0.35) | — | |
| SCHEMBL1767642 | 0.77 | ALOX5 (0.32) | — | |
| SCHEMBL6014787 | 0.76 | KDM5B (0.34) | — | |
| SCHEMBL20522044 | 0.76 | — | — | |
| SCHEMBL21218873 | 0.74 | AGBL2 (0.35) | — | |
| SCHEMBL20521581 | 0.74 | P2RX7 (0.36) | — | |
| SCHEMBL8721023 | 0.74 | TDP1 (0.34) | — | |
| SCHEMBL9117030 | 0.73 | CYP4F2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| CN-119490451-A | Compounds as positive modulators of calcium activated chloride channels | TMEM16A有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-111683926-B | Compounds of formula (I) | 企业治疗学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4215520-A1 | TMEM16A MODULATORS | TMEM16A LIMITED (GB) | 2023-07-26 | — | — | EP | disclosed |
| EP-3743406-B9 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2023-03-08 | — | — | EP | disclosed |
| EP-3743406-B1 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-20220395512-A1 | COMPOUNDS | TMEM16A LTD (GB) | 2022-12-15 | — | — | US | disclosed |
| US-11364246-B2 | Compounds | TMEM16A LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| US-8129397-B2 | Substituted thieno[2,3-d]pyrimidines as AMPA modulators | MSD OSS B.V. (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102056904-A | Indane derivatives as AMPA receptor modulators | ORGANON NV | 2011-05-11 | — | — | CN | disclosed |
| US-20110092539-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | N.V. ORGANON (NL) | 2011-04-21 | — | — | US | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| CN-101855227-A | Heterocyclic derivatives | ORGANON NV | 2010-10-06 | — | — | CN | disclosed |
| CN-101484448-A | Pyrazolealkanamide substituted thiophenes as AMPA potentiators | ORGANON NV (NL) | 2009-07-15 | — | — | CN | disclosed |
| US-20090131455-A1 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2009-05-21 | — | — | US | disclosed |
| EP-2041124-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. Organon (NL) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| WO-2008003452-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. ORGANON (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | IDO1 4724/4885TDO2 3889/4885 |
| US-11364246-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | IDO1 4787/4885TDO2 4689/4885 |
| US-20090131455-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIK5, GRIN1 | IDO1 1551/4885TDO2 3423/4885 |
| US-20220395512-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1A | IDO1 4802/4885TDO2 4720/4885 |
| US-20080255086-A1 | Heterocyclic Derivatives | GRIN2C, GRIN3A, GRIN1 | IDO1 1613/4885TDO2 3130/4885 |
| US-20110092539-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | GRIK5, GRIN3A, GRIK2 | IDO1 165/4885TDO2 1376/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | IDO1 4802/4885TDO2 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.